REGN10597

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

Advanced Solid TumorsAdvanced Solid TumoursClear-Cell Renal-Cell Carcinoma (ccRCC)Fallopian Tube CancerMelanomaOvarian CancerPrimary Peritoneal Cancer

Phase 1

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

RecruitingNCT06413680

Regeneron PharmaceuticalsMelanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors

Start: 2024-09-23End: 2030-02-03Target: 240Updated: 2026-04-28

A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies

Not yet recruitingCTIS2025-523399-22-00

Regeneron Pharmaceuticals Inc.Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)

Target: 52Updated: 2026-05-08

Phase 2

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

RecruitingNCT06787612

Regeneron PharmaceuticalsOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Start: 2025-05-28End: 2028-06-30Target: 297Updated: 2026-08-12

Related Papers

A phase 1/2 dose-escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-28